A Novel Strategy for Condition Assessment: Predicting Major Adverse Cardiovascular Events Post-Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients via CXCR7 and Its Ligand CXCL12

  • Hong Pan Department of Emergency,Huashan Hospital, Fudan University
  • Xiaoli Fan Department of Emergency,Huashan Hospital, Fudan University
  • Yu Liu Department of Emergency,Huashan Hospital, Fudan University
  • Gulijiakela Aishan Department of Emergency,Huashan Hospital, Fudan University
  • Jingwen Shao Department of Rehabilitation Medicine,Gongli Hospital of Shanghai Pudong New Area
DOI: https://doi.org/10.5937/jomb0-61266

Sažetak


Objective: The chemokine receptor CXCR7 and its ligand CXCL12 are critically involved in coronary microenvironment repair. Yet, their clinical relevance in diagnosing acute myocardial infarction (AMI) and forecasting post-percutaneous coronary intervention (PCI) major adverse cardiovascular events (MACE) has not been established. This study aims to explore the diagnostic utility of combined CXCR7 and CXCL12 testing in AMI and its predictive value for post-PCI MACE.  

Methods: This study enrolled 162 AMI patients and 54 healthy controls from January to June 2024. All patients received standardized PCI and were followed for 12 months. Serum CXCR7 and CXCL12 concentrations were determined via enzyme-linked immunosorbent assay (ELISA), while NT-proBNP was quantified with an automated biochemical analyzer. Comparative analyses of biomarker levels between groups were conducted, along with receiver operating characteristic (ROC) curve analysis for combined diagnostic performance. Dynamic changes in CXCR7/CXCL12 were also assessed in relation to postoperative MACE.

Results: Pre-treatment concentrations of CXCR7 and CXCL12 were markedly higher in the AMI group relative to controls. The combined detection achieved an AUC value of 0.812 for diagnosing AMI, superior to individual indicators (P<0.05). Both markers decreased significantly following PCI (P<0.05). Those who developed MACE exhibited higher post-treatment CXCR7 and CXCL12 levels compared to non-MACE cases; their combined AUC reached 0.806 for predicting post-PCI MACE (P<0.05). NT-proBNP showed an AUC of 0.893 for AMI diagnosis but no significant correlation with MACE occurrence (P>0.05).

Conclusion: The favorable diagnostic performance of CXCR7 and CXCL12 for AMI and post-PCI MACE suggests their potential as a novel protocol for the clinical assessment of AMI.  

Reference

1. Liu J, Zhou Y, Huang H, Liu R, Kang Y, Zhu T, et al. Impact of stress hyperglycemia ratio on mortality in patients with critical acute myocardial infarction: insight from american MIMIC-IV and the chinese CIN-II study. Cardiovasc Diabetol. 2023;22(1):281.
2. Warner ED, Ullah W, Farber J, Brailovsky Y, Vishnevsky A, Tchantchaleishvili V, et al. PCI for acute myocardial infarction in patients with a pre-existing LVAD, does it improve survival? Artif Organs. 2023;47(4):761-9.
3. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, Cachanado M, Durand-Zaleski I, et al. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial. JAMA. 2021;325(6):552-60.
4. Howard T, Majmundar M, Sarin S, Kumar A, Ajay A, Krishnaswamy A, et al. Predictors of Major Adverse Cardiovascular Events in Patients With Moderate Aortic Stenosis: Implications for Aortic Valve Replacement. Circ Cardiovasc Imaging. 2023;16(7):557-65.
5. Bayes-Genis A. NT-proBNP: Lower Is Always Better-Even in HFpEF. JACC Heart Fail. 2024;12(8):1456-8.
6. Henein MY, Vancheri S, Longo G, Vancheri F. The Role of Inflammation in Cardiovascular Disease. Int J Mol Sci. 2022;23(21).
7. Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, et al. CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications. Int J Biol Sci. 2023;19(11):3341-59.
8. Yang Y, Zhou Y, Wang Y, Wei X, Wu L, Wang T, et al. Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1beta/CXCR7-AMPK/p38-MAPK/IL-6 axis. Acta Diabetol. 2020;57(11):1315-26.
9. Murad HAS, Rafeeq MM, Alqurashi TMA. Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate. Ann Med. 2021;53(1):1598-612.
10. Benny M, Sharma M, Kulandavelu S, Chen P, Tian R, Ballengee S, et al. Protective role of CXCR7 activation in neonatal hyperoxia-induced systemic vascular remodeling and cardiovascular dysfunction in juvenile rats. Scientific reports. 2023;13(1):19538.
11. Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771-e862.
12. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-35.
13. Akhtar KH, Khan MS, Baron SJ, Zieroth S, Estep J, Burkhoff D, et al. The spectrum of post-myocardial infarction care: From acute ischemia to heart failure. Prog Cardiovasc Dis. 2024;82:15-25.
14. Premsagar P, Aldous C, Esterhuizen T. Cardiac scoring systems, coronary artery disease and major adverse cardiovascular events: A scoping review. S Afr Fam Pract (2004). 2023;65(1):e1-e8.
15. Wang T, Wang D, Sun Y, Zhuang T, Li X, Yang H, et al. Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer. Journal of experimental & clinical cancer research : CR. 2023;42(1):297.
16. Lu L, Li J, Jiang X, Bai R. CXCR4/CXCL12 axis: "old" pathway as "novel" target for anti-inflammatory drug discovery. Med Res Rev. 2024;44(3):1189-220.
17. Mause SF, Ritzel E, Deck A, Vogt F, Liehn EA. Engagement of the CXCL12-CXCR4 Axis in the Interaction of Endothelial Progenitor Cell and Smooth Muscle Cell to Promote Phenotype Control and Guard Vascular Homeostasis. Int J Mol Sci. 2022;23(2).
18. Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023;20(3):217-51.
19. Ghadge SK, Messner M, Seiringer H, Maurer T, Staggl S, Zeller T, et al. Smooth Muscle Specific Ablation of CXCL12 in Mice Downregulates CXCR7 Associated with Defective Coronary Arteries and Cardiac Hypertrophy. Int J Mol Sci. 2021;22(11).
20. Risteska M, Vladimirova-Kitova L, Andonov V. Serum NT-ProBNP potential marker of cirrhotic cardiomyopathy. Folia Med (Plovdiv). 2022;64(5):740-5.
Objavljeno
2025/10/03
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2025 Hong Pan, Xiaoli Fan, Yu Liu, Gulijiakela Aishan, Jingwen Shao

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.